Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis

Authors

• William Kelly

Publication/Presentation Date

2-2025

Volume

43

Issue

5

Published In/Presented At

DOI: 10.1200/JCO.2025.43.5_suppl.128

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article